Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03564821
Title	IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Massachusetts General Hospital
Indications	acute myeloid leukemia myelodysplastic syndrome chronic myelomonocytic leukemia
Therapies	Ivosidenib
Age Groups:	senior \| adult
Covered Countries	USA